

ABSTRACT

The Epstein-Barr virus (EBV)-encoded BARF1 (BamHI-A rightward frame-1) is expressed in EBV-positive malignancies such as nasopharyngeal carcinoma, EBV-associated gastric carcinoma, B cell lymphoma and nasal NK/T-cell lymphoma, and has been shown to have important role in oncogenesis. However, the mechanism by which BARF1 elicits its biological effects on EBV-positive malignant cells is unclear. In this study, the effects of BARF1 gene silencing on cell proliferation and apoptosis were investigated in EBV-positive malignant cells. We observed that silencing of BARF1 using RNAi significantly inhibits cell proliferation and induces apoptosis-mediated cell death by collapsing the mitochondrial membrane potential in AG876 and Hone-Akata cells. BARF1 knockdown also upregulates the expression of pro-apoptotic proteins and downregulates the expression of anti-apoptotic proteins. In BARF1-downregulated cells, the Bcl-2/BAX ratio is decreased. The caspase inhibitor z-VAD-fmk was found to rescue siBARF1-induced apoptosis in these cells. Immunoblot analysis showed significant increased levels of cleaved caspase 3 and caspase 9. Using western blotting analysis, we also observed a significant increase in cytochrome c level in the cytosolic fractions of BARF1-depleted cells. Immunoprecipitation and further immunoblot analysis revealed that depletion of BARF1 activated formation of apoptosome complex in BARF1-silenced cells. In conclusion, siRNA-mediated BARF1 downregulation induced caspase-dependent apoptosis via the mitochondrial pathway through modulation of Bcl-2/BAX ratio in AG876 and Hone-Akata cells. Targeting BARF1 using siRNA has potential to be developed as a novel therapeutic strategy in treatment of EBV-associated malignancies.

ABSTRAK

BARF1 (BamHI-A rightward frame-1) yang dikodkan oleh Epstein -Barr virus (EBV) diekspresikan di dalam malignansi positif EBV seperti karsinoma nasofarinks, karsinoma gastrik positif EBV, limfoma sel B dan limfoma sel NK/T hidung, telah terbukti mempunyai peranan yang penting dalam proses pembentukan kanser. Walau bagaimanapun, mekanisme dengan mana BARF1 menimbulkan kesan biologi pada sel-sel malignan positif EBV adalah tidak jelas. Dalam kajian ini, kesan gen BARF1 ke atas percambahan sel dan apoptosis telah disiasat dalam sel-sel malignan EBV positif. Kami mendapati bahawa pembungkaman BARF1 menggunakan RNAi dapat membendung percambahan sel dan mendorong sel mati secara apoptosis dengan meruntuhkan potensi membran mitokondria dalam sel-sel AG876 dan Hone-Akata dengan ketara. Pembungkaman BARF1 juga meningkatkan ekspresi protein pro-apoptosis dan menurunkan ekspresi protein anti-apoptosis. Di dalam sel-sel di mana BARF1 disenyapkan, nisbah Bcl-2/BAX berkurangan. Di dalam sel-sel ini juga, perencat caspase z-VAD-fmk didapati dapat menyelamatkan apoptosis yang disebabkan oleh siBARF1. Analisis blot imun menunjukkan peningkatan 'cleaved' caspase 3 dan 9 pada tahap signifikan. Menggunakan analisis 'Western blot', kami juga memerhatikan peningkatan yang ketara bagi tahap cytochrome c dalam pecahan sitosol sel-sel yang kehabisan BARF1. Kesimpulannya, pengurangan BARF1 yang disebabkan oleh siRNA menyebabkan apoptosis yang mana bergantung kepada caspase melalui laluan mitokondria secara modulasi nisbah Bcl-2/BAX di dalam sel-sel AG876 dan Hone-Akata. Pensasaran BARF1 menggunakan siRNA mempunyai potensi untuk dibangunkan sebagai strategi terapeutik novel dalam rawatan malignansi yang berkait dengan EBV.

ACKNOWLEDGEMENTS

In the name of Allah, the Most Gracious and the Most Merciful.

Alhamdulillah, all praises to Allah for the strengths and His blessings in completing this thesis.

I would like to express my heartfelt gratitude to my supervisor, Assoc. Prof. Dr. Ng Ching Ching. Thank you for your insightful advice and constructive criticisms throughout my study, that helped me to make necessary improvements. Your constant support and encouragement kept me motivated during the tenure of my study.

I am deeply indebted to all my friends in NPC and C8 Laboratory. Kok Siong, Chun Shen, See-too, Siang Ling, Yoon Ming, Mei Chee, Pei Li, Cheng Siang, Hui Jia, Xin Yue, Teik Min. You guys are smart, witty and your enthusiasm and passion in research is contagious. Thank you all for your friendship, constant help and support and valuable hints. Most importantly, thanks for being a good support system in good and bad times.

Last but not the least; I would like to thank my family. The constant inspiration and guidance kept me focused and motivated while I indulged in this madness. I can't express my gratitude in words, for the torch bearer in my life - my mom, whose unconditional love, support and sacrifices has been my greatest strength in life. I am grateful to my dad for giving me the life I ever dreamed and the huge faith he had in me. To my awesome sister and brother, thanks for sorting me out during difficult times. Your constant love, support and motivation is sincerely acknowledged. To my husband, thank you for understanding and tolerating my obsession and for all the sacrifices you made. To my lovely son, thank you for giving me so much happiness while I juggle with family and work. My thanks are also due to my close friends who have supported me in this long but fulfilling journey.

TABLE OF CONTENTS

| | |
|--|-------|
| Abstract | iii |
| Abstrak | iv |
| Acknowledgements | v |
| List of figures | xi |
| List of tables | xiv |
| List of symbols and abbreviations | xv |
| List of appendices | xviii |
| | |
| CHAPTER 1: INTRODUCTION | 1 |
| | |
| CHAPTER 2: LITERATURE REVIEW | 4 |
| 2.1 History of Epstein-Barr virus (EBV) | 4 |
| 2.2 Types of EBV | 4 |
| 2.3. Molecular biology of EBV | 5 |
| 2.4. Epstein-Barr virus infection | 5 |
| 2.5. EBV genes | 10 |
| 2.5.1. Epstein-Barr virus nuclear antigen 1 (EBNA1) | 10 |
| 2.5.2. Epstein-Barr virus nuclear antigen 2 (EBNA2) | 11 |
| 2.5.3. Epstein-Barr virus nuclear antigen 3A, 3B, 3C (EBNA3A, EBNA3B, EBNA3C) | 12 |
| 2.5.4. Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) | 13 |
| 2.5.5. Epstein-Barr virus-encoded RNAs (EBERs) | 13 |
| 2.5.6. BamHI-H fragment rightward reading frame 1 (BHRF1) | 14 |
| 2.5.7. BamHI-C fragment rightward reading frame 1 (BCRF1) | 14 |
| 2.5.8. BamHI-Z leftward reading frame 1 (BZLF1) | 15 |
| 2.5.9. Latent Membrane Protein 1 (LMP1) | 15 |
| 2.5.10. Latent Membrane Protein 2A and 2B (LMP2A and LMP2B) | 16 |
| 2.5.11. BamHI-A rightward frame 1 (BARF1) | 17 |

| | | |
|------------------------|--|----|
| 2.6. | EBV-associated cancers | 21 |
| 2.6.1. | Burkitt's Lymphoma | 21 |
| 2.6.2. | Hodgkin's disease | 23 |
| 2.6.3. | Non-Hodgkin's Lymphoma in Immunocompetent Individuals | 25 |
| 2.6.4. | Nasopharyngeal Carcinoma (NPC) | 26 |
| 2.6.5. | Gastric Carcinoma (GC) | 28 |
| 2.7. | Apoptosis | 29 |
| 2.7.1. | Apoptosis pathways | 30 |
| 2.7.2. | Caspases | 31 |
| 2.7.3. | The Bcl-2 family | 33 |
| 2.7.4. | Apoptosis and cell cycle related proteins | 35 |
| 2.7.5. | Modulation of apoptosis by Epstein-Barr virus | 37 |
| 2.8. | RNA interference | 38 |
| 2.8.1. | Introduction | 38 |
| 2.8.2. | RNAi machinery | 39 |
| 2.8.3. | Silencing mechanism of RNAi | 41 |
| 2.8.4. | RNAi application to viral infection | 42 |
| CHAPTER 3: METHODOLOGY | | 47 |
| 3.1. | Cell lines and cell culture conditions | 47 |
| 3.2. | Detection of BARF1 gene expression in EBV-positive malignant cells | 47 |
| 3.2.1. | Total RNA extraction | 47 |
| 3.2.2. | DNase treatment of total RNA | 48 |
| 3.2.3. | Reverse Transcription PCR (RT-PCR) | 49 |
| 3.2.4. | Cloning of the full length BARF1 into pCR4 sequencing vector | 50 |
| 3.2.5. | Transformation of TOP10 competent <i>E. coli</i> cells | 51 |
| 3.2.6. | Extraction of plasmid DNA from bacterial culture | 51 |
| 3.2.7. | Purity of the extracted plasmid | 52 |
| 3.2.8. | DNA sequencing of pCR4-BARF1 plasmid | 53 |
| 3.3. | Designing siRNA targeting the BARF1 mRNA | 53 |
| 3.4. | siRNA transfection | 55 |
| 3.5. | Analysis of gene expression in siRNA-treated cells | 54 |
| 3.5.1. | Total RNA extraction | 54 |
| 3.5.2. | DNase treatment of total RNA | 56 |
| 3.5.3. | cDNA synthesis | 56 |
| 3.5.4. | Real Time Quantitative PCR Assay | 57 |
| 3.5.5. | Semi-quantitative Reverse Transcription PCR (RT-PCR) | 59 |

| | | |
|--------------------|--|----|
| 3.6. | Cell proliferation assay | 60 |
| 3.6.1. | Trypan blue exclusion assay | 60 |
| 3.6.2. | WST-1 assay | 61 |
| 3.7. | Detection of apoptotic cells | 62 |
| 3.7.1. | Annexin V staining | 62 |
| 3.7.2. | Mitochondrial membrane potential | 63 |
| 3.8. | Western blot analysis | 64 |
| 3.8.1. | Preparation of cell lysates | 64 |
| 3.8.2. | Preparation of mitochondria and cytosolic fractions | 65 |
| 3.8.3. | Concentration of secreted protein | 66 |
| 3.8.4. | Measurement of protein concentration | 66 |
| 3.8.5. | SDS-polyacrylamide gel electrophoresis (PAGE) | 67 |
| 3.8.5.1. | Gel set-up | 67 |
| 3.8.5.2. | Protein preparation and gel electrophoresis | 69 |
| 3.8.5.3. | Transfer of proteins onto a polyvinylidene difluoride membrane | 69 |
| 3.8.6. | Protein signal detection | 70 |
| 3.8.6.1. | Antibody incubation | 70 |
| 3.8.6.2. | Signal detection | 70 |
| 3.9. | Apoptosis antibody array | 73 |
| 3.10. | Immunoprecipitation | 76 |
| 3.11. | Statistical analysis | 76 |
| CHAPTER 4: RESULTS | | 77 |
| 4.1. | BARF1 mRNA expression in EBV-positive cancer cells | 77 |
| 4.1.1. | BARF1 is expressed in AG876 and Hone-Akata cells | 77 |
| 4.2. | BARF1 siRNA suppresses the expression of BARF1 at the mRNA level | 79 |
| 4.2.1. | RNA quality and integrity analysis | 79 |
| 4.2.2. | Single transfection of BARF1 siRNA | 83 |
| 4.2.3. | Double transfection of BARF1 siRNA | 86 |
| 4.3. | siBARF1 suppresses the expression of BARF1 protein | 88 |
| 4.4. | Silencing of BARF1 expression inhibits cell proliferation | 90 |
| 4.4.1. | Trypan blue exclusion assay | 90 |
| 4.4.2. | WST-1 assay | 93 |

| | | |
|-----------------------|--|-----|
| 4.5. | BARF1 downregulation induces apoptosis-mediated cell death | 96 |
| 4.5.1. | Annexin V | 96 |
| 4.5.2. | PARP cleavage | 98 |
| 4.6. | Downregulation of BARF1 induces depolarization of mitochondrial membrane potential (MMP) | 99 |
| 4.6.1. | Flow cytometry analysis of MMP | 99 |
| 4.7. | BARF1 silencing upregulates the expression of pro-apoptotic proteins and downregulates the expression of anti-apoptotic proteins | 101 |
| 4.7.1. | Antibody array analysis of apoptosis-related proteins expression | 101 |
| 4.7.2. | Analysis of Bcl-2/BAX ratio in BARF1-silenced cells | 104 |
| 4.8. | Downregulation of BARF1 induces caspase dependent apoptosis | 109 |
| 4.8.1. | Flow cytometry analysis of MMP | 109 |
| 4.9. | BARF1 depletion increases cleavage of caspases 3 and 9 | 112 |
| 4.9.1. | Western blot analysis | 112 |
| 4.10. | BARF1 knockdown enhances cytochrome c release from mitochondria into cytosol | 113 |
| 4.10.1. | Immunoblotting for detection of cytochrome c | 113 |
| 4.11. | BARF1 silencing induces formation of apoptosome complex | 114 |
| 4.11.1. | Immunoprecipitation for Apaf-1 | 114 |
| CHAPTER 5: DISCUSSION | | 115 |
| 5.1. | RNAi experimental design | 116 |
| 5.2. | siRNA-mediated BARF1 downregulation inhibits cell proliferation in AG876 and Hone-Akata cells | 117 |
| 5.3. | Silencing of BARF1 induces apoptosis-mediated cell death in AG876 and Hone-Akata cells | 118 |
| 5.4. | Depletion of BARF1 induces apoptosis by collapsing mitochondrial membrane potential in AG876 and Hone Akata cells | 119 |
| 5.5. | BARF1 downregulation alters the expression of apoptotic molecules in AG876 and Hone-Akata cells | 120 |
| 5.6. | Silencing of BARF1 induces caspase-dependent apoptosis in AG876 and Hone-Akata cells | 121 |

| | |
|---------------------------|-----|
| 5.7. Limitations of study | 122 |
| 5.8. Roles of BARF1 | 123 |
| 5.9. Future directions | 127 |
| | |
| CHAPTER 6: CONCLUSION | 129 |
| | |
| References | 131 |
| | |
| Appendix I | 155 |

List of Figures

| | | |
|-------------|---|----|
| Figure 2.1. | The EBV genome | 7 |
| Figure 2.2. | The structure of the soluble hexameric molecule BARF1 | 18 |
| Figure 3.1. | Locations of the siRNAs in BARF1 mRNA | 54 |
| Figure 4.1. | RT-PCR amplification of BARF1 from AG876 and Hone-Akata cell lines | 78 |
| Figure 4.2. | Quality of RNA extracted from control and siBARF1-treated AG876 and Hone-Akata cells | 80 |
| Figure 4.3. | RIN values of RNA extracted from control and siBARF1-treated AG876 cells | 81 |
| Figure 4.4. | RIN values of RNA extracted from control and siBARF1-treated Hone-Akata cells | 82 |
| Figure 4.5. | qRT-PCR analysis of BARF1 mRNA expression in (a) AG876 and (b) Hone-Akata cells after single transfection with siNEG and siBARF1 | 85 |
| Figure 4.6. | qRT-PCR analysis of BARF1 mRNA expression in (a) AG876 and (b) Hone-Akata cells after double transfection with siNEG and siBARF1 | 87 |
| Figure 4.7. | BARF1 knockdown in AG876 and Hone-Akata cells using siBARF1-2 | 89 |
| Figure 4.8. | Number of viable AG876 cells after (a) single and (b) double transfection of siRNAs determined using the trypan blue exclusion assay | 91 |
| Figure 4.9. | Number of viable Hone-Akata cells after (a) single and (b) double transfection of siRNAs determined using the trypan blue exclusion Assay | 92 |

| | |
|--|-----|
| Figure 4.10. WST-1 analysis of the growth of (a) AG876 and (b) Hone-Akata cells after transfection with siNEG and siBARF1-2 | 94 |
| Figure 4.11. WST-1 analysis of the growth of (a) AG876 and (b) Hone-Akata cells after transfection with siNEG and siBARF1-3 | 95 |
| Figure 4.12. Silencing of BAF1 induced apoptosis-mediated cell death in AG876 and Hone-Akata cells | 97 |
| Figure 4.13. Detection of PARP cleavage in AG876 and Hone-Akata cells | 98 |
| Figure 4.14. Depletion of BAF1 induced depolarization of MMP in AG876 and Hone Akata cells | 100 |
| Figure 4.15. Expression of pro- and anti- apoptotic proteins in AG876 and Hone-Akata cells after transfection with siNEG and siBARF1-2, analyzed using human apoptosis antibody arrays | 103 |
| Figure 4.16. Histograms represent the fold change of apoptotic proteins derived from the fluorescence signal intensities of the arrays | 104 |
| Figure 4.17. Bcl-2/BAX ratio of control and siBARF1-transfected cells | 105 |
| Figure 4.18. Analysis of Bcl-2 and BAX mRNA expression in control and siBARF1-transfected AG876 and Hone-Akata cells | 106 |
| Figure 4.19. Analysis of Bcl-2 and BAX protein expression in control and siBARF1-transfected AG876 and Hone-Akata cells | 108 |
| Figure 4.20. MMP analysis of siBARF1-transfected AG876 and Hone-Akata cells pre-treated with z-VAD-fmk caspase inhibitor by flow cytometry | 110 |
| Figure 4.21. Percentage of cells with only JC-1 monomers (cells with collapsed MMP) | 111 |
| Figure 4.22. Western blot analysis of cleaved caspase 9 and cleaved caspase 3 in control and siBARF1-treated cells | 112 |
| Figure 4.23. Immunoblot for detection of cytochrome c level in mitochondrial fractions (MF) and cytoplasmic fractions (CF) | 113 |

| | |
|---|-----|
| Figure 4.24. Immunoprecipitation for Apaf-1 from cell lysates | 114 |
| Figure 5.1. Schematic diagram of proposed molecular mechanisms in the regulation of caspase-dependent mitochondrial-mediated apoptosis in BАРF1-silenced AG876 and Hone-Akata cells | 126 |

List of Tables

| | |
|---|----|
| Table 3.1: Components of RT-PCR and amplification conditions | 50 |
| Table 3.2: siRNA sequences against BARF1 open reading frame | 54 |
| Table 3.3: Components of the cDNA Synthesis Mix | 57 |
| Table 3.4: Oligonucleotide primers used in RT-PCR analysis | 60 |
| Table 3.5: Volume of M-PER used for different sizes of standard culture plates | 65 |
| Table 3.6: List of components for setting two 0.75-mm thick resolving gels | 68 |
| Table 3.7: List of components for setting stacking gels | 68 |
| Table 3.8: List of antibodies used in Western blotting and immunoprecipitation (IP) | 72 |
| Table 3.9: RayBio [®] Human Apoptosis Antibody Array G series | 75 |

List of symbols and abbreviations

| | |
|-----------------|---|
| × g | relative centrifugal force |
| °C | degree Celcius |
| µg | microgram |
| µl | microlitre |
| ADCC | antibody-dependent cellular cytotoxicity |
| AIDS | acquired immunodeficiency syndrome |
| Apaf-1 | Apoptotic protease-activating factor-1 |
| ASLV | Avian sarcoma leucosis virus |
| ATP | adenosine triphosphate |
| Bak | Bcl-2 homologous antagonist killer |
| BARF1 | BamH1-A Reading Frame-1 |
| BAX | Bcl-2-associated X |
| Bcl-2 | B-cell CLL/lymphoma 2 |
| BH | Bcl-2 homology |
| Bid | BH3 domain-containing proapoptotic Bcl-2 family protein |
| bp | base pairs |
| CAD | caspase-activated deoxyribonuclease |
| cDNA | complementary DNA |
| CD21 | cluster of differentiation 21 |
| CD95 | cluster of differentiation 95 |
| cIAP-2 | cellular inhibitor of apoptosis 2 |
| CO ₂ | carbon dioxide |
| COX IV | cytochrome c oxidase IV |
| CSF | colony stimulating factor |
| CTL | cytotoxic T lymphocyte |
| Cyto C | cytochrome c |
| dATP | deoxyadenosine triphosphate |
| DISC | death-inducing signaling complex |
| DNA | deoxyribonuclease acid |
| dNTP | deoxyribonucleotide triphosphate |
| dsRBD | dsRNA-binding domain |
| dsRNA | double-stranded RNA |
| DTT | Dithiothreitol |

| | |
|----------------|--|
| EBERs | EBV-encoded RNAs |
| EBNA | Epstein-Barr virus nuclear antigen |
| EBNA-LP | Epstein-Barr virus nuclear antigen leader protein |
| EBV | Epstein-Barr virus |
| EDTA | ethylenediaminetetraacetic acid |
| FADD | Fas-associated death domain |
| FasL | Fas ligand |
| FITC | fluoresceine-isothiocyanate |
| GAPDH | glyceraldehyde 3-phosphate dehydrogenase |
| GC | gastric carcinoma |
| h | hour |
| HCV | Hepatitis C virus |
| HIV-1 | human immunodeficiency virus 1 |
| HLA | human leukocyte antigen |
| HPV | human papillomavirus |
| H-Ras | Harvey rat sarcoma viral oncogene homolog |
| ICAD | inhibitor of caspase-activated deoxyribonuclease |
| IFN | interferon |
| IgG | immunoglobulin G |
| IL | interleukin |
| IM | infectious mononucleosis |
| IP | immunoprecipitation |
| JC-1 | mitochondrial membrane potential assay reagent |
| LB | Luria Bertani |
| LMP1 | Latent Membrane Protein-1 |
| LTR | long terminal repeat |
| M | molar |
| MAPK | mitogen-activated protein kinase |
| MHC | major histocompatibility complex |
| min | minute |
| miRNA | microRNA |
| ml | millilitre |
| MMP | mitochondrial membrane potential ($\Delta\Psi$) |
| mRNA | messenger RNA |
| NF- κ B | nuclear factor kappa-light-chain enhancer of activated B cells |

| | |
|------------|---|
| NK | natural killer |
| nm | nanometer |
| NPC | nasopharyngeal carcinoma |
| ORF | open reading frame |
| PARP | poly-(ADP-ribose) polymerase |
| PATAS | patas monkey kidney cells |
| PAZ domain | PIWI–Argonaute–Zwille domain |
| PBS | phosphate-buffered saline |
| PI | propidium iodide |
| PTGS | posttranscriptional gene silencing |
| qPCR | quantitative polymerase chain reaction |
| RISC | RNA induced silencing complex |
| RNAi | RNA interference |
| rpm | revolutions per minute |
| RPMI | Roswell Park Memorial Institute medium |
| s | second |
| SARS-CoV | SARS-associated coronavirus |
| SD | standard deviation |
| SDS-PAGE | sodium dodecyl sulfate polyacrylamide gel electrophoresis |
| siRNA | small interfering RNAs |
| TBS | tris-buffered saline |
| TRAF | tumor necrosis factor receptor-associated factor |
| UTR | untranslated region |
| UV | ultraviolet |
| w/v | weight/volume |
| WST-1 | water soluble tetrazolium salt-1 |
| z-VAD-fmk | caspase inhibitor VI |

List of Appendices

Appendix I

155